GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Epigenomics AG (STU:ECX) » Definitions » Shiller PE Ratio

Epigenomics AG (STU:ECX) Shiller PE Ratio : (As of May. 26, 2024)


View and export this data going back to . Start your Free Trial

What is Epigenomics AG Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Epigenomics AG Shiller PE Ratio Historical Data

The historical data trend for Epigenomics AG's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epigenomics AG Shiller PE Ratio Chart

Epigenomics AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Epigenomics AG Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Epigenomics AG's Shiller PE Ratio

For the Diagnostics & Research subindustry, Epigenomics AG's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Epigenomics AG's Shiller PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Epigenomics AG's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Epigenomics AG's Shiller PE Ratio falls into.



Epigenomics AG Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Epigenomics AG's E10 for the quarter that ended in Jun. 2023 is calculated as:

For example, Epigenomics AG's adjusted earnings per share data for the three months ended in Jun. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=-3.1/123.1404*123.1404
=-3.100

Current CPI (Jun. 2023) = 123.1404.

Epigenomics AG Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201309 -21.949 98.983 -27.306
201312 -23.320 99.356 -28.902
201403 -23.320 99.543 -28.848
201406 -18.734 99.543 -23.175
201409 -20.175 99.823 -24.888
201412 -30.262 99.543 -37.436
201503 -28.821 99.717 -35.591
201506 -21.616 100.417 -26.508
201509 -20.175 100.417 -24.740
201512 -5.764 99.717 -7.118
201603 -33.144 100.017 -40.807
201606 -23.057 100.717 -28.190
201609 -15.852 101.017 -19.324
201612 -7.205 101.217 -8.766
201703 -14.410 101.417 -17.497
201706 -25.939 102.117 -31.279
201709 -7.205 102.717 -8.638
201712 -15.050 102.617 -18.060
201803 -19.830 102.917 -23.727
201806 -16.780 104.017 -19.865
201809 -18.305 104.718 -21.525
201812 -19.165 104.217 -22.645
201903 -12.609 104.217 -14.898
201906 -18.410 105.718 -21.444
201909 -11.033 106.018 -12.815
201912 -27.780 105.818 -32.328
202003 -10.836 105.718 -12.622
202006 -11.180 106.618 -12.913
202009 -9.400 105.818 -10.939
202012 -8.600 105.518 -10.036
202103 -4.000 107.518 -4.581
202106 -4.200 108.486 -4.767
202109 3.200 109.435 3.601
202112 -2.950 110.384 -3.291
202203 -3.300 113.968 -3.566
202206 -1.600 115.760 -1.702
202209 -2.000 118.818 -2.073
202212 -8.000 119.345 -8.254
202303 -6.550 122.402 -6.589
202306 -3.100 123.140 -3.100

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Epigenomics AG  (STU:ECX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Epigenomics AG Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Epigenomics AG's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Epigenomics AG (STU:ECX) Business Description

Traded in Other Exchanges
Address
Geneststrasse 5, Berlin, BB, DEU, 10829
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.